GSK PLC
GS70
Company Profile
Business description
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Contact
79 New Oxford Street
LondonWC1A 1DG
GBRT: +44 2080475000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
66,841
Stocks News & Analysis
stocks
Chart of the Week: BHP’s growth story faces a reality check
China’s slowing economy could weigh on BHP’s future growth.
stocks
3 best ASX growth stocks to buy for the long term
Here’s three high-quality growth companies with wide moats.
stocks
The ASX data center stock flying under the radar
While markets chase AI hype, this data centre company offers real data center earnings and a visible growth pipeline.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,036.90 | 13.00 | -0.14% |
| CAC 40 | 8,377.86 | 4.57 | -0.05% |
| DAX 40 | 24,915.49 | 84.04 | -0.34% |
| Dow JONES (US) | 52,552.97 | 105.67 | -0.20% |
| FTSE 100 | 10,572.24 | 56.32 | 0.54% |
| HKSE | 25,008.60 | 327.50 | 1.33% |
| NASDAQ | 25,881.95 | 387.28 | -1.47% |
| Nikkei 225 | 66,835.54 | 1,915.97 | -2.79% |
| NZX 50 Index | 13,589.35 | 25.43 | -0.19% |
| S&P 500 | 7,533.77 | 38.63 | -0.51% |
| S&P/ASX 200 | 8,840.70 | 15.50 | -0.18% |
| SSE Composite Index | 3,882.41 | 73.17 | -1.85% |